This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background The prognosis of myocardial ischaemia with no obstructive coronaryarterydisease (INOCA) and its underlying vasomotor disorders, vasospastic angina (VSA) and microvascular angina (MVA), is not well defined.
Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundCoronary computed tomography angiography is increasingly used as the first‐line test for suspected coronaryarterydisease. PTP was calculated according to the 2013 and 2019 ESC guidelines.
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronaryarterydisease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Subscribe now Stenting stable coronaryarterydisease has not been convincingly proven to reduce the risk of future heart attacks or death 1. Whether stenting a narrowed coronaryartery improves symptoms such as chest pain (angina) or shortness of breath is a very different question. What About Symptoms?
Traditional Chinese herbal medicine (CHM) has been extensively used in cardiovascular disease in modern clinical practice, alone or in combination with conventional treatment. From inception until August 2023, we systematically searched five public literature databases to conduct the umbrella review.
I quickly reviewed the patient’s records and saw that she was a 53 year old woman with a history of BMI 40, but no other identifiable risk factors for coronaryarterydisease. The absence of risk factors for coronaryarterydisease does not mean a patient is not at risk for OMI.
Diamond and Forrester accomplished this by first establishing the prevalence of coronaryarterydisease based on how clinically likely patients with chest pain symptoms were found to have coronarydisease based on a coronary angiogram. Thanks for reading Dr. Anish Koka's Newsletter!
A CT Coronary angiogram was ordered. Here are the results: --Minimally obstructive coronaryarterydisease. --LAD A repeat troponin returned at 0.45 ng/mL, consistent with reperfused OMI, or Non-OMI. Now, with elevated troponins, Wellens' syndrome is likely. LAD plaque with 0-25 percent stenosis. CAD-RADS category 1. --No
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content